Genetic manipulation of bacteriophage T4 utilizing the CRISPR-Cas13b system [0.03%]
CRISPR-Cas13b系统在大肠杆菌T4噬菌体上的遗传操作研究
Yuvaraj Bhoobalan-Chitty,Mathieu Stouf,Marianne De Paepe
Yuvaraj Bhoobalan-Chitty
CRISPR-Cas type II and type V systems are inefficient in modifying bacteriophage T4 genome, due to hypermodification of its DNA. Here, we present a genome editing technique for bacteriophage T4 using the type VI CRISPR-Cas system. Using BzC...
Comparison of genotyping assays for detection of targeted CRISPR/Cas mutagenesis in highly polyploid sugarcane [0.03%]
用于检测高多倍体甘蔗目标CRISPR / Cas突变的基因分型测定的比较
Eleanor J Brant,David May,Ayman Eid et al.
Eleanor J Brant et al.
Sugarcane (Saccharum spp.) is an important biofuel feedstock and a leading source of global table sugar. Saccharum hybrid cultivars are highly polyploid (2n = 100-130), containing large numbers of functionally redundant hom(e)ologs in their...
Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine [0.03%]
CRISPR-Cas技术及其应用的新进展：精准医疗的变革者
Sarkar Sardar Azeez,Rahin Shareef Hamad,Bahra Kakamin Hamad et al.
Sarkar Sardar Azeez et al.
CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated proteins) has undergone marked advancements since its discovery as an adaptive immune system in bacteria and archaea, emerged as a potent gene-editing t...
Crop genome editing through tissue-culture-independent transformation methods [0.03%]
无组织培养的作物基因组编辑方法进展
Alejandro Sebiani-Calvo,Alejandro Hernández-Soto,Götz Hensel et al.
Alejandro Sebiani-Calvo et al.
Genome editing and plant transformation are crucial techniques in plant biotechnology, allowing for the precise modification of plant genomes to enhance agronomically essential traits. The advancement of CRISPR-based genome editing tools in...
Genetic and physiological characteristics of CsNPR3 edited citrus and their impact on HLB tolerance [0.03%]
CsNPR3编辑柑橘的遗传和生理特性及其对黄龙病耐受性的影响
Trishna Tiwari,Cecile Robertson,Choaa El-Mohtar et al.
Trishna Tiwari et al.
Huanglongbing (HLB) disease, caused by Candidatus Liberibacter asiaticus (CaLas), severely impacts citrus production, and currently, there is no cure. Developing HLB-resistant or tolerant cultivars is crucial, with modifying defense-related...
Yihan Wang,Gary C Hon
Yihan Wang
Large scale cancer genomic studies in patients have unveiled millions of non-coding variants. While a handful have been shown to drive cancer development, the vast majority have unknown function. This review describes the challenges of func...
Beyond the traditional distinctions of genome editing: evaluating a vulnerability framework [0.03%]
超越基因组编辑的传统区分：评估脆弱性框架
Ioanna Angelioudaki,Ana Ruxandra Badea,Martina Bodo et al.
Ioanna Angelioudaki et al.
Over 40 years ago, the 1982 Splicing Life report outlined the two distinctions that have orientated much of the normative and legal landscape of genetic intervention or genome editing since - that of somatic versus germline (or heritable in...
Targeting DLBCL by mutation-specific disruption of cancer-driving oncogenes [0.03%]
通过基因突变特异性干扰驱动癌症的原癌基因以靶向DLBCL
Najmeh Heshmatpour,S Maryam Kazemi,Niklas D Schmidt et al.
Najmeh Heshmatpour et al.
Diffuse large B cell lymphomas (DLBCL) are highly aggressive tumors. Their genetic complexity and heterogeneity have hampered the development of novel approaches for precision medicine. Our study aimed to develop a personalized therapy for ...
Knockout mutation in TaD27 enhances number of productive tillers in hexaploid wheat [0.03%]
TaD27敲除突变体易提高六倍体小麦的有效分蘖数
Muhammad Jawad Akbar Awan,Imran Amin,Awais Rasheed et al.
Muhammad Jawad Akbar Awan et al.
Recent advances allow the deployment of cluster regularly interspaced short palindromic repeats (CRISPR)-associated endonucleases (Cas) system for the targeted mutagenesis in the genome with accuracy and precision for trait improvement in c...
The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption [0.03%]
乙肝治愈的潜力：基于CRISPR的乙型肝炎病毒基因编辑概述
Zhi Q Yao,Madison B Schank,Juan Zhao et al.
Zhi Q Yao et al.
Hepatitis B virus (HBV) infection is a common cause of liver disease worldwide. The current antiviral treatment using nucleotide analogues (NAs) can only suppress de novo HBV replication but cannot eliminate chronic HBV infection due to the...